Piramal Pharma Ltd Stock Price Today (NSE: PPLPHARMA)
Fundamental Score
Piramal Pharma Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Piramal Pharma Ltd share price today is ₹136.54, up +1.77% on NSE/BSE as of 30 March 2026. Piramal Pharma Ltd (PPLPHARMA) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹24.56K (Cr). The 52-week high for PPLPHARMA share price is ₹240.95 and the 52-week low is ₹132.30. The company has a Return on Equity (ROE) of 1.11% and a debt-to-equity ratio of 0.60.
Piramal Pharma Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Piramal Pharma Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Piramal Pharma Share Price: A Conservative Value Investor's Perspective
The pharmaceutical sector, while often seen as recession-resistant due to constant healthcare needs, faces inherent risks. Regulatory hurdles, patent cliffs, and the ever-present threat of generic competition can erode profitability quickly. This analysis examines the Piramal Pharma share price (₹158.75 as of this writing) from a conservative value investing standpoint, prioritizing capital safety and long-term sustainability. A key metric raising concern is the Return on Capital Employed (ROCE) of 6.45%. This indicates the company's efficiency in generating profits from its invested capital.
The absence of a Price-to-Earnings (PE) ratio suggests the company may be currently unprofitable, a significant red flag for a value investor seeking established earnings power. This necessitates a deep dive into the underlying reasons for this lack of profitability and a thorough assessment of the company's turnaround strategy, if any. Compared to peers like
Mankind Pharma Ltd, which enjoys a strong reputation for consistent execution and potentially higher management quality, Piramal Pharma needs to demonstrate a clear path to improved operational efficiency and profitability.A ROCE of 6.45% raises questions about the company's economic moat. A strong moat, often built upon factors like brand reputation, patents, or cost advantages, allows a company to sustain above-average returns on capital over the long term. A low ROCE suggests that Piramal Pharma may lack a significant competitive advantage and could struggle to generate sustainable profits in the face of industry pressures. Further investigation is needed to identify potential sources of future moat development.
While this analysis provides an initial overview, a truly comprehensive evaluation of Piramal Pharma requires a much deeper dive. This assessment is part of an 80-parameter fundamental audit of Piramal Pharma Ltd, meticulously verified by Sweta Mishra. This comprehensive audit considers various financial ratios, cash flow analysis, debt levels, and qualitative aspects of the business to arrive at a more informed perspective. It is crucial to remember that this analysis is purely observational and does not constitute investment advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Piramal Pharma Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of PPLPHARMA across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Strong Operating Margins (15.15%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Strong Institutional Confidence (FII+DII: 45.16%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (1.11%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (6.45%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-539.22%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-8.83%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Weak Interest Coverage (1.52x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-29.18 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Piramal Pharma Ltd Financial Statements
Comprehensive financial data for Piramal Pharma Ltd including income statement, balance sheet and cash flow
About PPLPHARMA (Piramal Pharma Ltd)
Piramal Pharma Ltd is a dynamic force within the global pharmaceutical landscape, carving a niche as an integrated solutions provider. From its strategic base in India, the company... orchestrates a multifaceted approach encompassing research, development, and the manufacturing of both active pharmaceutical ingredients (APIs) and finished dosage forms. PPLPHARMA distinguishes itself through a commitment to innovation, evident in its pursuit of novel drug delivery systems and specialized formulations designed to address unmet medical needs. This commitment extends beyond its own product portfolio, as PPLPHARMA actively engages in collaborative partnerships with pharmaceutical companies worldwide, leveraging its expertise and infrastructure to accelerate the advancement of promising therapeutic candidates. Through a relentless focus on quality and efficiency, the company is positioned as a trusted partner in the ever-evolving world of healthcare. The company's operational model is built upon a foundation of advanced manufacturing capabilities and stringent regulatory compliance. With a network of state-of-the-art facilities strategically located across various geographies, Piramal Pharma Ltd offers a seamless, end-to-end solution for pharmaceutical companies seeking to outsource key stages of their drug development and manufacturing processes. This comprehensive offering spans from early-stage research and development to late-stage commercial production, ensuring that clients receive tailored support every step of the way. PPLPHARMA emphasizes sustainability in its operations, reflecting a commitment to responsible manufacturing practices and environmental stewardship. This holistic approach, combined with its unwavering focus on customer satisfaction, solidifies the company's reputation as a reliable and ethical partner within the industry. Beyond its core contract development and manufacturing (CDMO) services, Piramal Pharma Ltd also maintains a growing portfolio of proprietary pharmaceutical products targeting specific therapeutic areas. These branded offerings are distributed through a robust global network, enabling the company to directly impact patient outcomes and improve healthcare access. PPLPHARMA’s dedication to innovation and quality is underscored by its ongoing investment in research and development, constantly exploring new avenues for therapeutic advancement and operational efficiency. The company’s forward-looking vision positions it as a key player in shaping the future of pharmaceutical manufacturing and healthcare delivery, driven by a commitment to excellence and a passion for improving lives worldwide.
Company Details
Key Leadership
Corporate Events
PPLPHARMA Share Price: Frequently Asked Questions
What is the current share price of Piramal Pharma Ltd (PPLPHARMA)?
As of 30 Mar 2026, 12:03 pm IST, Piramal Pharma Ltd share price is ₹136.54. The PPLPHARMA stock has a market capitalisation of ₹24.56K (Cr) on NSE/BSE.
Is PPLPHARMA share price Overvalued or Undervalued?
PPLPHARMA share price is currently trading at a P/E ratio of 0.00x, compared to the industry average of 31.77x. Based on this relative valuation, the Piramal Pharma Ltd stock appears to be Fairly Valued against its sector peers.
What is the 52-week high and low of PPLPHARMA share price?
The 52-week high of PPLPHARMA share price is ₹240.95 and the 52-week low is ₹132.30. These values are updated daily from NSE/BSE price data.
What factors affect the Piramal Pharma Ltd share price?
Key factors influencing PPLPHARMA share price include quarterly earnings growth (Sales Growth: -8.83%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Piramal Pharma Ltd a good stock for long-term investment?
Piramal Pharma Ltd shows a 5-year Profit Growth of N/A% and an ROE of 1.11%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.60 before investing in PPLPHARMA shares.
How does Piramal Pharma Ltd compare with its industry peers?
Piramal Pharma Ltd competes with major peers in the Pharmaceuticals. Investors should compare PPLPHARMA share price P/E of 0.00x and ROE of 1.11% against the industry averages to determine competitive standing.
What is the P/E ratio of PPLPHARMA and what does it mean?
PPLPHARMA share price has a P/E ratio of N/Ax compared to the industry average of 31.77x. Investors pay ₹N/A for every ₹1 of annual earnings.
How is PPLPHARMA performing according to Bull Run's analysis?
PPLPHARMA has a Bull Run fundamental score of 2.3/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does PPLPHARMA belong to?
PPLPHARMA operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Piramal Pharma Ltd share price.
What is Return on Equity (ROE) and why is it important for PPLPHARMA?
PPLPHARMA has an ROE of 1.11%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Piramal Pharma Ltd generates profits from shareholders capital.
How is PPLPHARMA debt-to-equity ratio and what does it indicate?
PPLPHARMA has a debt-to-equity ratio of 0.60, which indicates moderate leverage that should be monitored.
What is PPLPHARMA dividend yield and is it a good dividend stock?
PPLPHARMA offers a dividend yield of 0.08%, meaning you receive ₹0.08 annual dividend for every ₹100 invested in Piramal Pharma Ltd shares.
How has PPLPHARMA share price grown over the past 5 years?
PPLPHARMA has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in PPLPHARMA and why does it matter?
Promoters hold 34.86% of PPLPHARMA shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Piramal Pharma Ltd.
What is PPLPHARMA market capitalisation category?
PPLPHARMA has a market capitalisation of ₹24555 crores, placing it in the Large-cap category.
How volatile is PPLPHARMA stock?
PPLPHARMA has a beta of N/A. A beta > 1 suggests the Piramal Pharma Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is PPLPHARMA operating profit margin trend?
PPLPHARMA has a 5-year average Operating Profit Margin (OPM) of 15.15%, indicating the company's operational efficiency.
How is PPLPHARMA quarterly performance?
Recent quarterly performance shows Piramal Pharma Ltd YoY Sales Growth of -8.83% and YoY Profit Growth of -539.22%.
What is the institutional holding pattern in PPLPHARMA?
PPLPHARMA has FII holding of 30.27% and DII holding of 14.89%. Significant institutional holding often suggests professional confidence in the Piramal Pharma Ltd stock.